Pulse Biosciences (NASDAQ:PLSE) Announces Earnings Results

Pulse Biosciences (NASDAQ:PLSE) posted its earnings results on Thursday. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.06, FiscalAI reports. The company had revenue of ($0.09) million for the quarter, compared to the consensus estimate of $0.23 million.

Here are the key takeaways from Pulse Biosciences’ conference call:

• Company secured IDE approvals for both the nPulse cardiac catheter and the nPulse cardiac clamp and expects to commence and complete pivotal enrollment in 2026, supported by European feasibility data showing 100% procedural success at six months, 96% at one year, and 90% freedom from AF at 12 months.
• The Vibrance soft-tissue rollout remains a tightly controlled market-development launch with Q4 revenue of $264,000; PRECISE benign thyroid nodule enrollment should complete in the next few months and expand to 100 patients to support reimbursement and regulatory filings.
• Cash ended 2025 at $80.7 million with Q4 operating cash use of $14.8 million and widening non-GAAP losses, and the company filed a $200 million shelf registration—signaling potential need for future capital and dilution risk.
• Pulse materially strengthened its intellectual property and partnerships—adding 67 issued and 77 pending patents in 2025 (totaling 250 granted and 180 pending) while pursuing mapping integrations and an MD Anderson collaboration to accelerate commercial and oncologic applications.

Pulse Biosciences Stock Performance

Shares of NASDAQ:PLSE opened at $21.42 on Friday. The company has a market capitalization of $1.45 billion, a PE ratio of -19.83 and a beta of 1.77. The stock has a fifty day moving average of $16.35 and a 200-day moving average of $16.08. Pulse Biosciences has a one year low of $12.56 and a one year high of $26.30.

Key Stories Impacting Pulse Biosciences

Here are the key news stories impacting Pulse Biosciences this week:

• Positive Sentiment: Q4 EPS beat analyst expectations — Pulse reported a loss of $0.26 per share vs. consensus -$0.32, beating estimates and showing a smaller-than-expected loss. This helped limit downside after the print. Read More.
• Positive Sentiment: Clinical/business update: company highlighted strong procedural results for its endocardial nPulse catheter (100% freedom from AF at 6 months, 96% procedural success), supporting long‑term product potential and commercialization story. Read More.
• Neutral Sentiment: Investor outreach: Pulse will present at the 46th Annual TD Cowen Healthcare Conference — useful for visibility and investor Q&A but not an immediate revenue driver. Read More.
• Neutral Sentiment: Inducement equity grants: the board awarded equity inducements to two new employees under Nasdaq Rule 5635(c)(4). Standard hiring practice; could be seen as modestly dilutive over time but routine. Read More.
• Negative Sentiment: Revenue missed expectations — reported revenue was effectively flat/negative ($-0.09M) vs. the consensus ~$0.23M, raising near-term commercialization and cash‑flow concerns for some investors. Read More.
• Negative Sentiment: Insider selling: recent filings show insiders sold roughly $0.94M combined in two transactions, which investors may interpret as a negative signal on near‑term insider conviction. Read More. Read More.

Wall Street Analyst Weigh In

A number of brokerages recently commented on PLSE. Wall Street Zen upgraded Pulse Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a report on Thursday, January 22nd. Oppenheimer reaffirmed an “outperform” rating and issued a $30.00 price objective on shares of Pulse Biosciences in a report on Friday. Finally, Mizuho set a $30.00 price objective on shares of Pulse Biosciences in a research report on Friday, February 6th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $30.00.

Insiders Place Their Bets

In other Pulse Biosciences news, insider Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $23.53, for a total transaction of $470,600.00. Following the transaction, the insider directly owned 43,298 shares in the company, valued at approximately $1,018,801.94. The trade was a 31.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders sold 80,000 shares of company stock valued at $1,876,200. Company insiders own 74.60% of the company’s stock.

Institutional Investors Weigh In On Pulse Biosciences

Institutional investors have recently bought and sold shares of the business. Bank of America Corp DE grew its stake in Pulse Biosciences by 2.7% during the 3rd quarter. Bank of America Corp DE now owns 804,960 shares of the company’s stock valued at $14,248,000 after acquiring an additional 21,424 shares in the last quarter. State Street Corp boosted its holdings in shares of Pulse Biosciences by 6.0% during the fourth quarter. State Street Corp now owns 447,067 shares of the company’s stock worth $6,138,000 after purchasing an additional 25,187 shares during the period. Brooklyn Investment Group grew its position in Pulse Biosciences by 330.7% during the fourth quarter. Brooklyn Investment Group now owns 130,340 shares of the company’s stock valued at $1,844,000 after purchasing an additional 100,081 shares in the last quarter. Portolan Capital Management LLC purchased a new position in Pulse Biosciences during the third quarter valued at approximately $1,809,000. Finally, UBS Group AG increased its stake in Pulse Biosciences by 53.4% in the 3rd quarter. UBS Group AG now owns 76,856 shares of the company’s stock valued at $1,360,000 after buying an additional 26,739 shares during the period. 76.95% of the stock is currently owned by institutional investors and hedge funds.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.